Article
Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft.
Neoplasia (New York, N.Y.) - 1 Oct 2026
González Jèssica, Cai Xueting, Diao Wenjing, Roué Gaël, València-Clua Kevin, Olmo-González Daniel, González-Cao María, Jain Anisha, Jantus-Lewintre Eloisa, Giménez-Capitán Ana, Molina-Vila Miguel Angel, Codony-Servat Jordi, Cao Peng, Rosell Rafael
Abstract excerpt
BACKGROUND: KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC) is currently treated with KRAS G12C covalent inhibitors, such as sotorasib, or RAS (ON) G12-selective inhibitors; however, response rates and progression-free survival remain limited, with recurrence occurring in most patients. Although mechanisms of resistance in KRAS G12C cell lines are multifarious, they have been attributed to EGFR...
Read the complete abstract on PubMedTopics
- Animals
- Humans
- Carcinoma, Non-Small-Cell Lung
- Mice
- Receptors, Cytoplasmic and Nuclear